SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. J Rheumatol 1993; 20: 5758.
  • 2
    Van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 57981.
  • 3
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 4
    Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S1008.
  • 5
    Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 7314.
  • 6
    Pincus T. The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol 2006; 33: 8347.
  • 7
    Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006; 65: 8202.
  • 8
    Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008; 35: 213647.
  • 9
    Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-joint count, disease activity score, Health Assessment Questionnaire (HAQ), multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 2008; 35: 6039.
  • 10
    Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008; 35: 2015.
  • 11
    Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008; 47: 3459.
  • 12
    Van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999; 26: 70511.
  • 13
    Keystone E, van der Heijde D, Mason D Jr, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two–week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 331929.
  • 14
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 15
    Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23: S939.
  • 16
    Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Kunath AM, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010; 62: 1819.
  • 17
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 15974.
  • 18
    Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006; 33: 214652.
  • 19
    Sokka T, Pincus T. Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 71322.
  • 20
    Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 278492.
  • 21
    Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol 2005; 32: 5757.
  • 22
    Pincus T, Oliver AM, Bergman MJ. How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ. Rheum Dis Clin North Am 2009; 35: 799812.